Related Experiment Video
Updated: Aug 9, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach
R Villuendas1, J L Steegmann, M Pollán
1Molecular Pathology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. rvilluendes@cnio.es rvilluendas@cnio.es
Abstract:
The use of the tyrosine kinase inhibitor imatinib, which blocks the enzymatic action of the BCR-ABL fusion protein, has represented a critical advance in chronic myeloid leukemia (CML) treatment. However, a subset of patients initially fails to respond to this treatment. Use of complementary DNA (cDNA) microarray expression profiling allows the identification of genes whose expression is associated with imatinib resistance. Thirty-two CML bone marrow samples, collected before imatinib treatment, were hybridized to a cDNA microarray containing 6500 cancer genes, and analyzed using bootstrap statistics. Patients refractory to interferon-alpha treatment were evaluated for cytogenetic and molecular responses for a minimum of 12 months. A set of 46 genes was differentially expressed in imatinib responders and non-responders. This set includes genes involved in cell adhesion (TNC and SCAM-1), drug metabolism (cyclooxygenase 1), protein tyrosine kinases and phosphatases (BTK and PTPN22). A six-gene prediction model was constructed, which was capable of distinguishing cytogenetic response with an accuracy of 80%. This study identifies a set of genes that may be involved in primary resistance to imatinib, suggesting BCR-ABL-independent mechanisms.
Insights
This study identified 46 genes associated with imatinib resistance in chronic myeloid leukemia (CML) patients. A six-gene model accurately predicted treatment response, suggesting BCR-ABL-independent resistance mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Imatinib therapy is a breakthrough for chronic myeloid leukemia (CML).
- A significant subset of CML patients exhibit primary resistance to imatinib.
- Understanding resistance mechanisms is crucial for improving CML treatment outcomes.
Purpose of the Study:
- To identify genes associated with primary imatinib resistance in CML.
- To develop a predictive model for imatinib response in CML patients.
- To explore potential BCR-ABL-independent mechanisms of imatinib resistance.
Main Methods:
- Utilized cDNA microarray expression profiling on 32 CML bone marrow samples before treatment.
- Analyzed 6500 cancer genes using bootstrap statistics.
- Evaluated cytogenetic and molecular responses in patients refractory to interferon-alpha therapy.
Main Results:
- Identified a set of 46 differentially expressed genes between imatinib responders and non-responders.
- Discovered genes involved in cell adhesion, drug metabolism, and protein tyrosine kinases/phosphatases.
- Developed a six-gene prediction model with 80% accuracy in distinguishing cytogenetic response.
Conclusions:
- A specific gene expression profile is linked to primary imatinib resistance in CML.
- The identified genes may play a role in BCR-ABL-independent resistance pathways.
- The predictive model offers potential for early identification of non-responders to imatinib therapy.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase